Author Question: The A-B-A-B design is a slight variation on the A-B-A design, in which treatment is returned at the ... (Read 103 times)

melly21297

  • Hero Member
  • *****
  • Posts: 565
The A-B-A-B design is a slight variation on the A-B-A design, in which treatment is returned at the end of the experiment. Under what conditions would this be most desirable?
 
  a. if the researcher is still not sure whether the treatment was effective
   b. if the treatment has some beneficial therapeutic effect
  c. if the treatment did not produce the desired effect the first time it was presented
  d. if the participant enjoyed the treatment

Question 2

A potential ethical problem with using the A-B-A design in a therapeutic context is that it
 
  a. does not seem to be useful for certain kinds of disorders.
   b. entails ending in a non-treatment condition.
  c. often aggravates the problem the treatment is meant to treat.
  d. does not involve enough time in treatment to address all a behavior.



atrochim

  • Sr. Member
  • ****
  • Posts: 331
Answer to Question 1

B

Answer to Question 2

B



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

Before a vaccine is licensed in the USA, the Food and Drug Administration (FDA) reviews it for safety and effectiveness. The CDC then reviews all studies again, as well as the American Academy of Pediatrics and the American Academy of Family Physicians. Every lot of vaccine is tested before administration to the public, and the FDA regularly inspects vaccine manufacturers' facilities.

Did you know?

The modern decimal position system was the invention of the Hindus (around 800 AD), involving the placing of numerals to indicate their value (units, tens, hundreds, and so on).

Did you know?

According to the Migraine Research Foundation, migraines are the third most prevalent illness in the world. Women are most affected (18%), followed by children of both sexes (10%), and men (6%).

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

Did you know?

Approximately one in four people diagnosed with diabetes will develop foot problems. Of these, about one-third will require lower extremity amputation.

For a complete list of videos, visit our video library